Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J, Fransson S, Siaw JT, Treis D, Van den Eynden J, Chand D, Umapathy G, Ruuth K, Svenberg P, Wessman S, Shamikh A, Jacobsson H, Gordon L, Stenman J, Svensson PJ, Hansson M, Larsson E, Martinsson T, Palmer RH, Kogner P, Hallberg B. Guan J, et al. Among authors: van den eynden j. Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4):a002550. doi: 10.1101/mcs.a002550. Print 2018 Aug. Cold Spring Harb Mol Case Stud. 2018. PMID: 29907598 Free PMC article.
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma.
Siaw JT, Javanmardi N, Van den Eynden J, Lind DE, Fransson S, Martinez-Monleon A, Djos A, Sjöberg RM, Östensson M, Carén H, Trøen G, Beiske K, Berbegall AP, Noguera R, Lai WY, Kogner P, Palmer RH, Hallberg B, Martinsson T. Siaw JT, et al. Among authors: van den eynden j. Cell Rep. 2020 Sep 22;32(12):108171. doi: 10.1016/j.celrep.2020.108171. Cell Rep. 2020. PMID: 32966799 Free article.
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M, Umapathy G, Lai WY, Lind DE, Witek B, Guan J, Mendoza-Garcia P, Masudi T, Claeys A, Chuang TP, El Wakil A, Arefin B, Fransson S, Koster J, Johansson M, Gaarder J, Van den Eynden J, Hallberg B, Palmer RH. Borenäs M, et al. Among authors: van den eynden j. EMBO J. 2021 Feb 1;40(3):e105784. doi: 10.15252/embj.2020105784. Epub 2021 Jan 7. EMBO J. 2021. PMID: 33411331 Free PMC article.
Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells.
Siaw JT, Gabre JL, Uçkun E, Vigny M, Zhang W, Van den Eynden J, Hallberg B, Palmer RH, Guan J. Siaw JT, et al. Among authors: van den eynden j. Cancers (Basel). 2021 Apr 15;13(8):1909. doi: 10.3390/cancers13081909. Cancers (Basel). 2021. PMID: 33921066 Free PMC article.
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.
Szydzik J, Lind DE, Arefin B, Kurhe Y, Umapathy G, Siaw JT, Claeys A, Gabre JL, Van den Eynden J, Hallberg B, Palmer RH. Szydzik J, et al. Among authors: van den eynden j. Nat Commun. 2021 Nov 24;12(1):6813. doi: 10.1038/s41467-021-27057-2. Nat Commun. 2021. PMID: 34819497 Free PMC article.
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G. Bokhari AA, et al. Among authors: van den eynden j. Lung Cancer. 2022 Sep;171:103-114. doi: 10.1016/j.lungcan.2022.07.010. Epub 2022 Jul 25. Lung Cancer. 2022. PMID: 35933914 Free article.
36 results